Nature Communications (Jan 2021)
Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box
- Janette Reader,
- Mariëtte E. van der Watt,
- Dale Taylor,
- Claire Le Manach,
- Nimisha Mittal,
- Sabine Ottilie,
- Anjo Theron,
- Phanankosi Moyo,
- Erica Erlank,
- Luisa Nardini,
- Nelius Venter,
- Sonja Lauterbach,
- Belinda Bezuidenhout,
- Andre Horatscheck,
- Ashleigh van Heerden,
- Natalie J. Spillman,
- Anne N. Cowell,
- Jessica Connacher,
- Daniel Opperman,
- Lindsey M. Orchard,
- Manuel Llinás,
- Eva S. Istvan,
- Daniel E. Goldberg,
- Grant A. Boyle,
- David Calvo,
- Dalu Mancama,
- Theresa L. Coetzer,
- Elizabeth A. Winzeler,
- James Duffy,
- Lizette L. Koekemoer,
- Gregory Basarab,
- Kelly Chibale,
- Lyn-Marié Birkholtz
Affiliations
- Janette Reader
- Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria
- Mariëtte E. van der Watt
- Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria
- Dale Taylor
- Drug Discovery and Development Centre (H3D), University of Cape Town
- Claire Le Manach
- Drug Discovery and Development Centre (H3D), University of Cape Town
- Nimisha Mittal
- Division of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California San Diego
- Sabine Ottilie
- Division of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California San Diego
- Anjo Theron
- Next Generation Health, Council for Scientific and Industrial Research
- Phanankosi Moyo
- Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria
- Erica Erlank
- Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, and Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service
- Luisa Nardini
- Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, and Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service
- Nelius Venter
- Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, and Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service
- Sonja Lauterbach
- Department of Molecular Medicine and Hematology, Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand
- Belinda Bezuidenhout
- Department of Molecular Medicine and Hematology, Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand
- Andre Horatscheck
- Drug Discovery and Development Centre (H3D), University of Cape Town
- Ashleigh van Heerden
- Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria
- Natalie J. Spillman
- Division of Infectious Diseases, Department of Medicine, Washington University
- Anne N. Cowell
- Division of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California San Diego
- Jessica Connacher
- Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria
- Daniel Opperman
- Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria
- Lindsey M. Orchard
- Department of Biochemistry & Molecular Biology and the Huck Centre for Malaria Research, Pennsylvania State University
- Manuel Llinás
- Department of Biochemistry & Molecular Biology and the Huck Centre for Malaria Research, Pennsylvania State University
- Eva S. Istvan
- Division of Infectious Diseases, Department of Medicine, Washington University
- Daniel E. Goldberg
- Division of Infectious Diseases, Department of Medicine, Washington University
- Grant A. Boyle
- Drug Discovery and Development Centre (H3D), University of Cape Town
- David Calvo
- Global Health Incubator Unit, GlaxoSmithKline (GSK)
- Dalu Mancama
- Next Generation Health, Council for Scientific and Industrial Research
- Theresa L. Coetzer
- Department of Molecular Medicine and Hematology, Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand
- Elizabeth A. Winzeler
- Division of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California San Diego
- James Duffy
- Medicines for Malaria Venture, International Center Cointrin
- Lizette L. Koekemoer
- Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, and Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service
- Gregory Basarab
- Drug Discovery and Development Centre (H3D), University of Cape Town
- Kelly Chibale
- Drug Discovery and Development Centre (H3D), University of Cape Town
- Lyn-Marié Birkholtz
- Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria
- DOI
- https://doi.org/10.1038/s41467-020-20629-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
Here, Reader et al. screen the Medicines for Malaria Venture Pandemic Response Box in parallel against Plasmodiumasexual and liver stage parasites, stage IV/V gametocytes, gametes, oocysts and as endectocides. They identify two potent transmission-blocking drugs: a histone demethylase inhibitor ML324 and the antitubercular SQ109.
